EXCLISIVE: Ocean Biomedical ' s JV Partner Virion Therapeutics Dosed First Patients In Novel Immunotherapy Study For Chronic Hepatitis B

Ocean Biomedical, Inc. OCEA announces that its joint venture partner, Virion Therapeutics, has dosed its first patient in the Phase 1b clinical trial of its investigational VRON-0200 immunotherapy. Virion Therapeutics is a clinical-stage biotechnology company developing novel T cell-based…#oceanbiomedical #ocea #viriontherapeutics #virion #hongkong #newzealand #suecurrie #cooofvirion #vron0200 #jonathankurtis
Source: Reuters: Health - Category: Consumer Health News Source Type: news